Saturday, January 17, 2026 2:44:06 PM
Independent peer reviewers don't count for approvals. They only see what NWBO feeds them -- never saw the REAL trial results, just the totally manipulated trial after changing the protocol, primary endpoint, comparator, even added a R/R leg after the trial was DONE!!!
FDA sure saw all the NWBO B.S. and they wouldn't even accept an application as they didn't buy the trial.
Dr. Liau, Ashcan, even the JAMA Oncology don't count for any commercial review. Just not how FDA isn't accepting the trial, so NWBO had to run to another country to try to salvage their future. And now look -- years of review without an approval. Let's see what happens. Even approval in UK is going to be pretty poor revenue potential based on the other personalized oncology treatment market. Oncology market in UK is less that 10% of the U.S.
FDA sure saw all the NWBO B.S. and they wouldn't even accept an application as they didn't buy the trial.
Dr. Liau, Ashcan, even the JAMA Oncology don't count for any commercial review. Just not how FDA isn't accepting the trial, so NWBO had to run to another country to try to salvage their future. And now look -- years of review without an approval. Let's see what happens. Even approval in UK is going to be pretty poor revenue potential based on the other personalized oncology treatment market. Oncology market in UK is less that 10% of the U.S.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
